Jeroen Van den Bossche's questions to Inventiva (IVA) leadership • Q4 2021
Question
Jeroen Van den Bossche of KBC Securities asked about the rationale for the LEGEND combination trial, questioning if it was based solely on existing clinical data for lanifibranor and empagliflozin or if new preclinical data was used. He also inquired about the company's future commercialization strategy for lanifibranor, cedirogant, and odiparcil, specifically whether they plan to partner or go to market themselves.
Answer
CMO Michael Cooreman and executive Pierre Broqua explained that the strong rationale for the combination is built upon extensive existing human clinical data and the well-understood mechanisms of both drugs, making new non-clinical studies unnecessary. Executive Frederic Cren outlined the strategy: find a big pharma partner for lanifibranor, likely after Phase III data; cedirogant development is fully managed and funded by AbbVie; and for odiparcil, the company continues to seek a partner due to resource constraints.